• EZ Cap™ Human PTEN mRNA: Redefining Tumor Suppressor Restora

  2026-07-27

  Discover how EZ Cap™ Human PTEN mRNA advances tumor suppressor gene mRNA research with enhanced stability and translational efficiency. This article uniquely dissects molecular mechanisms and experimental design strategies for next-generation cancer and gene therapy research.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-07-27

  Wang et al. reveal how the METTL16-SENP3-LTF axis confers resistance to ferroptosis and promotes tumorigenesis in hepatocellular carcinoma (HCC). These findings clarify a novel epitranscriptomic mechanism underlying iron metabolism and cell death evasion in HCC, suggesting new therapeutic targets for sensitizing tumors to ferroptotic cell death.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate f

  2026-07-26

  This study presents a reproducible 13-step synthesis of deuterium-labeled degarelix acetate, enabling its use as a robust internal standard in pharmacokinetics and metabolism research. The methodological advances improve analytical accuracy for clinical development of androgen-related therapeutics.

• 7-Ethyl-10-hydroxycamptothecin: Protocols for Advanced Colon

  2026-07-25

  7-Ethyl-10-hydroxycamptothecin (SN-38) delivers reliable, dual-action inhibition in metastatic colon cancer models by targeting DNA topoisomerase I and disrupting oncogenic transcriptional regulators. This article provides stepwise protocols, troubleshooting, and new assay designs that leverage APExBIO’s high-purity SN-38 for reproducible, mechanistically rich in vitro research.

• Optimizing Cytokine Assays with Pexmetinib (ARRY-614): Pract

  2026-07-24

  This article delivers scenario-driven, evidence-based strategies for using Pexmetinib (ARRY-614, SKU B6012) to enhance reproducibility, sensitivity, and interpretability in cell viability and cytokine modulation assays. Drawing on recent structural and mechanistic insights, it addresses real laboratory challenges and provides actionable recommendations for biomedical researchers.

• CX-4945 (Silmitasertib): A Precise CK2 Inhibitor for Cancer

  2026-07-24

  CX-4945 (Silmitasertib) is a highly selective, ATP-competitive CK2 inhibitor that induces apoptosis and cell cycle arrest in cancer models. It blocks CK2-mediated phosphorylation, impacting PI3K/Akt signaling and tumor growth. The compound is backed by robust in vitro and in vivo data, supporting its utility in oncology workflows.

• TMRE Mitochondrial Membrane Potential Assay Kit: Applied Wor

  2026-07-23

  Unlock high-sensitivity, quantitative mitochondrial health detection with the TMRE mitochondrial membrane potential assay kit. This guide delivers actionable protocols, advanced troubleshooting, and translational insights, integrating the latest NECSO research to empower mitochondrial function analysis in apoptosis and sodium-overload models.

• Sulfo-NHS-LC-Biotin: Technical Guide for Surface Protein Lab

  2026-07-23

  Sulfo-NHS-LC-Biotin is a water-soluble reagent for irreversibly labeling primary amines on cell surface or soluble proteins under aqueous conditions, enabling stable capture and detection using biotin-avidin systems. It is not suitable for intracellular or reversible biotinylation applications due to its membrane-impermeable and irreversible chemistry.

• NSAIDs and Canine Osteosarcoma: Cytotoxicity and Mechanisms

  2026-07-22

  This study evaluates the effects of deracoxib and piroxicam on the viability of canine osteosarcoma cells in vitro, revealing concentration-dependent cytotoxicity without apoptosis induction. The findings inform ongoing efforts to identify safer antiproliferative agents for bone tumor management.

• Stat3 Drives Fyn Kinase-Mediated Dopaminergic Neurodegenerat

  2026-07-22

  This study establishes Stat3 as a critical downstream effector of Fyn kinase in dopaminergic neuron loss and microglial activation, using a zebrafish model. These findings illuminate the Fyn-Stat3-NF-κB axis as a driver of neurodegeneration, refining our understanding of Parkinson's disease mechanisms and informing experimental gene editing approaches.

• Quercetin (SKU N1841): Reliable PI3K Inhibitor for Lab Assay

  2026-07-21

  This article provides scenario-driven guidance for researchers using Quercetin (SKU N1841) as a PI3K inhibitor in cell viability and apoptosis assays. Integrating recent mechanistic discoveries and protocol best practices, it demonstrates how APExBIO’s Quercetin offers reproducible, high-purity solutions for cancer and liver disease research. Practical Q&A blocks address common workflow challenges, product selection, and data interpretation, supported by quantitative literature and direct product links.

• Diethylmaleate (SKU B6151): Redox Control for Biomedical Ass

  2026-07-21

  This article examines how Diethylmaleate (SKU B6151) from APExBIO enables robust, reproducible redox modulation in cell viability, cytotoxicity, and resistance studies. We explore key laboratory scenarios, underpinning each with peer-reviewed data and practical protocol guidance to help researchers achieve consistent, interpretable results in oxidative stress and toxicology workflows.

• Artesunate: Applied Protocols for Cancer Research Innovation

  2026-07-20

  Artesunate, a potent artemisinin derivative, is redefining in vitro cancer workflows with its dual action as an AKT/mTOR pathway inhibitor and ferroptosis inducer. This article translates advanced assay design, troubleshooting, and protocol optimization into practical steps for small cell lung and esophageal squamous cell carcinoma research.

• Lipid Transfection Reagents: Enabling Next-Gen Drug Resistan

  2026-07-20

  Explore how Lipo3K Transfection Reagent is empowering translational researchers to unravel multidrug resistance mechanisms in cancer. This thought-leadership article integrates mechanistic insights, highlights recent breakthroughs in lipid raft-mediated chemoresistance, and provides practical protocol guidance for high-efficiency nucleic acid delivery in challenging cell models.

• CYR61-Mediated Migrasome Delivery Restores Osteogenesis in I

  2026-07-19

  This study reveals that CYR61, delivered via migrasomes, is pivotal in restoring the migration and osteogenic differentiation of irradiated bone marrow mesenchymal stem cells (IR BMSCs), addressing a major obstacle in osteoradionecrosis of the jaw (ORNJ) repair. The findings highlight an integrin/ERK signaling axis as a therapeutic target, with robust experimental workflows supporting translational potential.

16452 records 1/1097 page Next 12345 下5页 Last page